Rhythm Pharma CEO Gottesdeiner to Step Down After FDA Filing

Rhythm Pharmaceuticals (NASDAQ: RYTM) announced late Monday that president and CEO Keith Gottesdiener will step down from his executive roles and from the board of directors after the company submits its lead drug for FDA review. Gottesdiener has been Rhythm CEO and board member since 2011. A search for his successor is underway.